Christopher Pugh

Apr 24, 2024 | nature.com | Mike B. Barnkob |Yale Michaels |Philip Macklin |Uzi Gileadi |Salvatore Valvo |Margarida Rei | +14 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-47424-z, published online 12 April 2024In this article the title was incorrectly written as ‘Semmaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells’ but should have been ‘Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells’. The original article has been corrected.

Apr 12, 2024 | nature.com | Yale Michaels |Philip Macklin |Uzi Gileadi |Salvatore Valvo |Margarida Rei |Corinna A. Kulicke | +14 more

AbstractSemaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely understood. Here we demonstrate that Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 are upregulated on stimulated CD8+ T cells, allowing tumour-derived SEMA3A to inhibit T cell migration and assembly of the immunological synapse.

Mar 21, 2024 | thelancet.com | Jonathan Barratt |Debbie Sharp |Christopher Pugh

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Feb 1, 2024 | bmjoncology.bmj.com | Laure Marignol |Christopher Pugh

Genetic markersSolid tumourTumour biomarkersMultiple lines of evidence confirm the strong association between the presence of hypoxia in solid tumours and poorer outcomes in patients with cancer resulting from both more aggressive tumour cell behaviour and impaired responses to therapy.1 2 With well over 12 000 articles published in the past 5 years alone (source, PubMed), the importance of hypoxia in cancer is indisputable.